Výsledky vyhledávání - "Adenocarcinoma

HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma

Autor: Josep Tabernero, Lin Shen, Elena Elimova, Geoffrey Ku, Tianshu Liu, Kohei Shitara, Xiao Lin, Lisa Boyken, Huiyan Li, Jonathan Grim, Jaffer Ajani

Publikováno v: Scientia

HER2-positive gastroesophageal adenocarcinomas (GEAs) are common cancers with high mortality and the treatment options for advanced/metastatic disease are limited. Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8abe02b2f9a46d36f7a0e174a7f7ba3f
https://pubmed.ncbi.nlm.nih.gov/36000541

Zobrazit plný text záznamu

Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report

Autor: Oriol Mirallas, Marc Bosch-Schips, Nuria Pardo, Anton Aubanell, Maria Teresa Salcedo-Allende, Ana Callejo, Patricia Iranzo, Josep Tabernero, Enriqueta Felip

Publikováno v: Scientia

Metastatic hepatic rupture; Non-small cell lung carcinoma; Tyrosine kinase inhibitor Ruptura hepática metastásica; Carcinoma de pulmón de células no pequeñas; Inhibidor de la tirosina quinasa Ruptura hepàtica metastàtica; Carcinoma de pulmó d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12effaf284a4dd804af516ae6f0a6da6
https://hdl.handle.net/11351/8026

Zobrazit plný text záznamu

Quality of life with first-line pembrolizumab for PD-L1epositive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study

Autor: Van Cutsem, E., Valderrama, A., Bang, Yung-Jue, Fuchs, C. S., Shitara, Kohei, Janjigian, Y. Y., Qin, S., Larson, T. G., Shankaran, V., Stein, S., Norquist, J. M., Kher, U., Shah, S., Alsina, Maria, Universitat Autònoma de Barcelona

Publikováno v: ESMO Open
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Scientia

Background In the randomised phase III KEYNOTE-062 study, pembrolizumab was non-inferior to chemotherapy for overall survival in patients with programmed death-ligand 1 (PD-L1)-positive [combined positive score (CPS) ≥1] advanced gastric/gastroesop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::574353a1a2b648f0617caf724448b5cb
https://lirias.kuleuven.be/handle/123456789/680659

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání